We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.
AVEO

Delisted

AVEO was delisted on the 19th of January, 2023.

Back to rankings

44 hedge funds and large institutions have $16M invested in AVEO Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

0% more funds holding

Funds holding: 44 → 44 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

38% less capital invested

Capital invested by funds: $25.7M → $16M (-$9.69M)

60% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 10

Holders
44
Holders Change
–
Holders Change %
0%
% of All Funds
1.1%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
6
Increased
4
Reduced
10
Closed
6
Calls
$8K
Puts
–
Net Calls
+$8K
Net Calls Change
-$49K

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$667K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$156K
3
Renaissance Technologies
Renaissance Technologies
New York
+$99K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$26.1K
5
TSS
Two Sigma Securities
New York
+$9.83K

Top Sellers

Rank Fund Capital Flow
1
SCM
Sarissa Capital Management
Connecticut
-$200K
2
SIM
Spark Investment Management
New York
-$91.2K
3
BCM
Bridgeway Capital Management
Texas
-$35.4K
4
TRCT
Tower Research Capital (TRC)
New York
-$29.5K
5
Citadel Advisors
Citadel Advisors
Florida
-$28.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$5.6M – – –
PA
2
Perceptive Advisors
New York
$1.68M – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$1.48M +$99K +14,850 +6%
NLVP
4
New Leaf Venture Partners
New York
$1.4M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$1.33M +$26.1K +3,916 +2%
BIT
6
BlackRock Institutional Trust
California
$1.05M – – –
SCM
7
Sarissa Capital Management
Connecticut
$917K -$200K -30,000 -15%
CAM
8
Cormorant Asset Management
Massachusetts
$587K – – –
6CM
9
683 Capital Management
New York
$540K +$667K +100,000 New
DVC
10
Deer VI & Co
New York
$365K – – –
BCM
11
Bridgeway Capital Management
Texas
$249K -$35.4K -5,309 -10%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$163K – – –
Jacobs Levy Equity Management
13
Jacobs Levy Equity Management
New Jersey
$156K -$11.1K -1,660 -5%
Susquehanna International Group
14
Susquehanna International Group
Pennsylvania
$127K +$156K +23,470 New
Northern Trust
15
Northern Trust
Illinois
$57K +$2.45K +367 +4%
SIM
16
Spark Investment Management
New York
$51K -$91.2K -13,686 -59%
CC
17
Cannell & Co
New York
$48K -$25.4K -3,812 -30%
Tudor Investment Corp
18
Tudor Investment Corp
Connecticut
$45K – – –
Bank of New York Mellon
19
Bank of New York Mellon
New York
$33K -$2.82K -423 -6%
EWM
20
Evercore Wealth Management
New York
$21K – – –
California Public Employees Retirement System
21
California Public Employees Retirement System
California
$18K – – –
State Street
22
State Street
Massachusetts
$14K – – –
Connor, Clark & Lunn Investment Management (CC&L)
23
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$10K – – –
GC
24
Guggenheim Capital
Illinois
$10K – – –
BFA
25
BlackRock Fund Advisors
California
$9K +$2.52K +378 +30%
1
2

AVEO Hedge Fund Activity: Q4 2016 in Review

44 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q4 2016, worth a combined $16M — down 38% from $25.7M a quarter earlier.

Fund positioning in AVEO was balanced in Q4 2016: 6 funds opened new positions, 6 closed out, 4 added to existing stakes and 10 trimmed.

The largest buyer was 683 Capital Management, opening a new position worth an estimated $667K. The largest seller was Sarissa Capital Management, cutting an estimated $200K.

  • 44 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q4 2016, unchanged from Q3 2016.
  • Funds reported $16M of AVEO Pharmaceuticals, Inc. stock for Q4 2016, down 38% quarter-over-quarter.
  • 6 funds opened new AVEO Pharmaceuticals, Inc. positions in Q4 2016 and 6 closed out, a net change of 0 holders.
  • The largest AVEO Pharmaceuticals, Inc. buyer in Q4 2016 was 683 Capital Management, an estimated $667K added.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q4 2016 was Sarissa Capital Management, an estimated $200K sold.

Based on aggregated 13F filings for Q4 2016.